Cytokinetics (CYTK) Corporate presentation summary

Mission and vision

• Aims to improve healthspan for people with cardiovascular and neuromuscular diseases of impaired muscle function.

• Vision 2030 targets leadership in muscle-focused biopharma, broad access in 15+ countries, and reaching over 100,000 patients globally.

• Focus on innovation, patient-centric culture, and equitable access.

Product portfolio and pipeline

• MYQORZO (aficamten) approved in the US, China, and EU for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

• Pipeline includes aficamten for pediatric oHCM and non-obstructive HCM (nHCM), omecamtiv mecarbil for HFrEF, and ulacamten for HFpEF.

• Multiple Phase 3 trials ongoing or planned, including ACACIA-HCM (nHCM) and COMET-HF (HFrEF).

Clinical evidence and differentiation

• SEQUOIA-HCM Phase 3: MYQORZO significantly improved exercise capacity, symptoms, and cardiac structure vs. placebo.

• MAPLE-HCM Phase 3: Aficamten superior to metoprolol in improving exercise capacity, symptoms, and biomarkers.

• Integrated safety analysis shows low incidence of serious adverse events and manageable safety profile.